Autoinflammatory

Inpatient study 5495 Adult Stills Dz (AOSD) hospitalizations (2016–2019). Pts w/ HLH (6.2%) had higher mortality (9% vs 1.5%). Deatjs Independent predictors: DIC (OR 6.1), liver failure (7.2), Infx (3.7), resp failure (6.9),thrombotic microangiopathy (14) https://t.co/BQsbVnw2Ir https://t.co/mbn9JuN7ow

Links:

Dr. John Cush @RheumNow( View Tweet )
3 yr German laboratory study of 71,597 laboratory tests, found 238 positive tests for 13 myositis autoAbs in 209 patients. Pos. results due to Idiopathic inflammatory myopathy in 37(18%), other inflammatory rheum Dz 90 (43%) or NO Rheum Dx 82 (39%) https://t.co/KKg0X1AyU1 https://t.co/FfVfufaUm4

Links:

Dr. John Cush @RheumNow( View Tweet )
Pollution and Autoimmunity (7.12.2024) Dr. Jack Cush reviews the news and journal articles from the past week on https://t.co/V10S4oVFsv. https://t.co/c4Eo4EpOj8

Links:

Dr. John Cush @RheumNow( View Tweet )
Full read, comprehensive review of NLRP3 inflammasome & its role in inate immunity (eg, infections), but also lifestyle (obesity, diabetes, NAFLD, heart/lung disease, periodontitis) and autoimmune diseases https://t.co/rCk9ncEsGA https://t.co/qc9eSIAVYe

Links:

Dr. John Cush @RheumNow( View Tweet )
ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes https://t.co/46g8ek286u https://t.co/FEFq4vkiPk

Links:

Dr. John Cush @RheumNow( View Tweet )
hidradenitis.jpg

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Jack Cush, MD

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma

Read Article
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/gvRzYpFl5i https://t.co/uSISWG3foy

Links:

Dr. John Cush @RheumNow( View Tweet )
The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn

Links:

Dr. John Cush @RheumNow( View Tweet )
Systematic review of Autoimmune Dz (AID) & myelodysplastic syndrome (MDS) finds AIDs found in 17.5% of MDS pts. With AID, MDS mortality rates ranged 15.3-67%. Why this relationship exists is unclear. https://t.co/SZNH8v2CIT https://t.co/QTGiqUCqqs

Links:

Dr. John Cush @RheumNow( View Tweet )
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw

Links:

Dr. John Cush @RheumNow( View Tweet )
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Links:

Dr. John Cush @RheumNow( View Tweet )
Systemic Score in AOSD to Predict Life-threatening Complications Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria. https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2

Links:

Dr. John Cush @RheumNow( View Tweet )
The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f

Links:

Dr. John Cush @RheumNow( View Tweet )
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn

Links:

Dr. Antoni Chan @synovialjoints( View Tweet )
NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8

Links:

Artem Minalyan, MD, DABOM @AMinalyan( View Tweet )
Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA

Links:

Annals of the Rheumatic Diseases @ARD_BMJ( View Tweet )
#Behcet’s #syndrome is increasing in the UK ? ⬆️ Detection ? Changing population demographics ? Other reasons Poster discussion POS0258 #EULAR2024 @RheumNow @eular_org @Pr1yankaC https://t.co/SEzmJnFMhM

Links:

Janet Pope @Janetbirdope( View Tweet )
Loved the talk on #VEXAS by @maferradastrong today at #EULAR2024 ! Amazing pictures to explain cellular level pathophysiology! Look for abnormal signs that arent otherwise explained to try to get to the diagnosis. @rheumnow https://t.co/YZmAqmFHpE

Links:

Bella Mehta @bella_mehta( View Tweet )
STAR responder may be the way to go! Less placebo effect than CREST. Better in patients with low systemic activity. https://t.co/mMYOKfG2gS

Links:

Bella Mehta @bella_mehta( View Tweet )
FDA has approved upadacitinib (Rinvoq), for use in pediatric patients (age >2 years) w/ active polyarticular juvenile idiopathic arthritis (pJIA) & psoriatic arthritis (PsA), after inadequate resp/intolerance to TNFi. Also available as oral solution. https://t.co/dZ21V2cKwR https://t.co/QADVP2w3Tz

Links:

Dr. John Cush @RheumNow( View Tweet )
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/qJykCPMn4U https://t.co/zVOTxLkW9R https://t.co/3I4eOfPYWk

Links:

Dr. John Cush @RheumNow( View Tweet )
No Great Options for Treating VEXAS For patients w/ VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed. https://t.co/xCQYHwgUH9 https://t.co/N5Q03izr8u https://t.co/csIixQO3sJ

Links:

Dr. John Cush @RheumNow( View Tweet )
Vexas

No Great Options for Treating VEXAS

MedPage Today

For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.

Among 110 patients in the

Read Article
Study of 187 Oligoarticular JIA pts - Remission was achieved w/ DMARDs in 65.8%; predictors of nonresponse (DMARD resistance) - Elevated CRP (> 1.1 mg/dL' OR 1.3) & and high JADAS-71 at Dx (> 15.8; OR 1.7) https://t.co/oPajnplXUL https://t.co/TnrknASCzb

Links:

Dr. John Cush @RheumNow( View Tweet )
Cutoffs for sJADAS10 An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the sJADAS10, a disease activity measure distinguish patients with ID, MiDA, MoDA, HDA. https://t.co/A0kIqiOWFE https://t.co/zShqs781W1

Links:

Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

Best of 2022: Five Mistakes When Diagnosing Still’s Disease

Jack Cush, MD
Thermometer
Adult-onset Still's presents an interesting and diagnostic challenge when encountered. Here are 5 tips to improve your diagnostic acumen for this febrile disorder. Read Post

Best of 2022: Myths & Misconceptions with Febrile Disorders

Rachel Tate, DO
Myth vs reality
Still’s disease and autoinflammatory disorders are rare conditions unified by recurrent fevers and inflammation of skin, joints, and other organs. While labs often support the diagnosis, these conditions are best diagnosed by genetic testing, or by specific criteria (in the absence of a genetic test). The following is a table that lists common misconceptions (myths) and their clarifying explanations. Read Post

Featured Video

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.